Forge Therapeutics may be barely two years old, but it has attracted the attention of many experts in the antibiotic development world thanks to its team's work targeting metalloenzymes.
Forge Therapeutics Excites Big Guns In Antibiotic World
Emerging Company Profile: Forge Therapeutics, which licensed intellectual property from the University of California San Diego in 2015, is aiming to have developed a novel class of antibiotic to treat Gram-negative superbugs, with its first drug candidate entering clinical development in 2020. The company has just announced an expanded research and discovery pact with Evotec in the UK, and boasts an impressive line-up of scientific advisors.
More from Start-Ups & SMEs
• By
The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
• By
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
More from Business
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
• By
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.